For example in prostate cancer, PSMA-PET (or alternatively choline-PET) is now recommended for patients with biochemical recurrence who are considered for salvage treatment,6 with growing evidence that PSMA-PET is superior to choline-PET for this purpose.78 For primary staging of prostate cancer, PET is currently not recommended by the guidelines, but evidence that PSMA-PET/MRI may also be beneficial for these indications is emerging.79,80. The gene discussed is FOLH1; the disease is prostate cancer.